Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer

NCT01790126 is registered in ClinicalTrials.gov with Aragon Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01790126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01790126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Lead sponsor
Aragon Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 4, 2013
Completion date
March 1, 2019
Enrollment
90 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer